KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to 13.32%.

  • Charles River Laboratories International's EBIT Margin rose 16900.0% to 13.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.5%, marking a year-over-year decrease of 95000.0%. This contributed to the annual value of 5.61% for FY2024, which is 93300.0% down from last year.
  • Latest data reveals that Charles River Laboratories International reported EBIT Margin of 13.32% as of Q3 2025, which was up 16900.0% from 9.7% recorded in Q2 2025.
  • Charles River Laboratories International's 5-year EBIT Margin high stood at 19.26% for Q2 2022, and its period low was 16.73% during Q4 2024.
  • Over the past 5 years, Charles River Laboratories International's median EBIT Margin value was 14.89% (recorded in 2022), while the average stood at 12.88%.
  • Per our database at Business Quant, Charles River Laboratories International's EBIT Margin skyrocketed by 42200bps in 2022 and then tumbled by -298400bps in 2024.
  • Quarter analysis of 5 years shows Charles River Laboratories International's EBIT Margin stood at 19.09% in 2021, then decreased by -22bps to 14.89% in 2022, then decreased by -12bps to 13.12% in 2023, then plummeted by -228bps to 16.73% in 2024, then soared by 180bps to 13.32% in 2025.
  • Its EBIT Margin stands at 13.32% for Q3 2025, versus 9.7% for Q2 2025 and 7.59% for Q1 2025.